ClinicalTrials.gg

Herpes Zoster clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 299 studies for Herpes Zoster across more than 10 countries. 55 are recruiting or about to start. 223 of them are mainly about Herpes Zoster (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
188
Recruiting
37
Status unknown
19
Active, not recruiting
18
Not yet recruiting
15
Terminated
12

Phase

Phase 3
70
Phase 2
69
Phase 1
46
Phase 4
33
Early Phase 1
3

Where

United States
95
China
51
Canada
22
Korea, Republic of
20
Germany
17
Australia
17

Who develops what

Add Herpes Zoster to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 19 programs from 11 companies, 17 with this as their studies’ main aim; 2 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Chongqing Zhifei Biological Products, GlaxoSmithKline and Sinovac Biotech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
shingrixRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07481604 · Aribio Lab Co., Ltd. · Phase 2 · live · comparator · “Shingrix” · registered Mar 2026
  • NCT07205796 · Shenzhen Shenxin Biotechnology Co., Ltd · Phase 2 · live · comparator · “Shingrix” · registered Sep 2025
  • NCT06932523 · Sinopharm · Phase 2 · live · comparator · “Shingrix (GSK)” · registered Apr 2025
  • NCT06801509 · Sinocelltech Group Limited · Phase 2 · live · comparator · “Shingrix®” · registered Jan 2025
  • NCT06581575 · Immorna Biotherapeutics, Inc. · Phase 2 · live · comparator · “Shingrix” · registered Aug 2024
GlaxoSmithKline88% of its industry studies88 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
shingrixPhase 4 trial recorded☆ Track1 live phase-3 study: NCT05371080GlaxoSmithKline
CHO cellPhase 4 trial recorded☆ Track2 live phase-3 studies: NCT06447779, NCT07293065MAXVAX Biotechnology Limited Liability Company

The 2 in phase 3 with the nearest primary completion, of 19 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.CVI-VZV-001 · Aribio Lab Co., Ltd. · Phase 2 main aimvs shingrixNCT07481604 Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above — primary endpoint: Geometric Mean Fold Rise (GMFR) of Anti-VZV gE Antibody · 135 enrolled
  • 10 Mar 2027 est.A zoster mRNA vaccine SYS6017 · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07354659 Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above — primary endpoint: solicited adverse events · 800 enrolled
  • 31 Jul 2027 est.CHO cell · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07892989 Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above — primary endpoint: solicited adverse events · 496 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Herpes Zoster studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Opioids 4

Coming up

19studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger. 3 (8%) take children under 18. 2 (5%) are for women only and 0 (0%) for men only; 13 (35%) take healthy volunteers.

Recruiting studies that take each age, of 37
AgeWomenMen
103 (8%)2 (5%)
1821 (57%)20 (54%)
3024 (65%)23 (62%)
4031 (84%)31 (84%)
5034 (92%)33 (89%)
6532 (86%)31 (84%)
7530 (81%)30 (81%)
8529 (78%)29 (78%)

Across all 299 studies, recruiting or not: 18% stop at 75 or younger and 9% at 65; 5% take children; 1% are for women only and <1% for men only; 44% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Herpes Zoster studies take

Of 40 phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo9–22 · 21 studies——
Phase 219 mo12–27 · 22 studies——
Phase 316 mo10–45 · 40 studies16 mo9–45 · 33 studies—
Phase 430 mo14–45 · 19 studies——
Interventional, no phase13 mo9–24 · 34 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 299. Browse all 299 → or search them.